Abstract: This disclosure describes genetically modified photosynthetic microorganisms, including Cyanobacteria, that contain one or more exogenous genes encoding a diacylglycerol acyltransferase, a phosphatidate phosphatase, and/or an acetyl-CoA carboxylase, and which are capable of producing increased amounts of fatty acids and/or synthesizing triglycerides.

Abstract: This disclosure describes genetically modified photosynthetic microorganisms, including Cyanobacteria, that contain one or more exogenous genes encoding a diacylglycerol acyltransferase, a phosphatidate phosphatase, and/or an acetyl-CoA carboxylase, and which are capable of producing increased amounts of fatty acids and/or synthesizing triglycerides.

Abstract: Compositions and methods for recombinant protein production and, more particularly, fusion polypeptides, polynucleotides encoding fusion polypeptides, expression vectors, kits, and related methods for recombinant protein production.

Abstract: The present invention provides very safe lactic acid bacteria and lactic acid bacteria preparations which are effective in prevention and therapy of allergies and/or in lowering of the blood neutral fat level. The present invention also provides pharmaceutical products and food or drink products which contain, as an active ingredient, a composition that contains cultured cells of the lactic acid bacterium Pediococcus acidilactici R037 or a treated product thereof.

Abstract: An object of the present invention is to provide a composition for removing aldehyde. Specifically, the present invention relates to an aldehyde-removing composition comprising a microorganism belonging to the genus Gluconobacter having aldehyde-degrading activity, or extracts thereof or disrupted cells thereof, wherein the microorganism belonging to the genus Gluconobacter has higher aldehyde-degrading activity than aldehyde-generating activity.

Abstract: Novel compositions and methods of reducing microbial resistance to antimicrobial agents and treating infections are disclosed. In particular, compositions and methods of inhibiting efflux pump activity, treating infection and methods of enhancing antimicrobial activity of antimicrobial agents are provided.

Abstract: A culture vessel and a method of growing cells in a culture vessel. The culture vessel includes a container and a plurality of agitators. The container receives a medium and cells. The plurality of agitators is positioned to contact the medium when received in the container and configured to promote suspension of the cells in the medium upon oscillation of the agitators. The agitators are at least one of coupled to and formed integrally with the container such that there is no relative movement there-between. The method includes receiving a medium and cells in a container and oscillating the medium such that the cells traverse along a longitudinal direction of the container.

Abstract: Disclosed herein is a novel gluconacetobacter strain having cellulose producing activity. Specifically, the present invention relates to a novel gluconacetobacter strain producing nano-structured cellulose in a highly efficient manner. The cellulose produced by the strain, due to its superb thermodynamic properties, can be characterized as nano-structured bacterial cellulose and therefore utilized as a bio-nano-fiber. Particularly, the cellulose can be impregnated with a resin to form a cellulose-based resin which can be effectively adapted for a substrate for a liquid crystal display (LCD).

Abstract: The present invention is directed to methods for delaying a plant development process comprising exposing a plant or plant part to one or more bacteria or enzymes. In specific embodiments, the one or more bacteria are selected from the group consisting of Rhodococcus spp., Pseudomonas chloroaphis, Brevibacterium ketoglutamicum, and a mixture comprising any combination of these bacteria. Apparatuses for delaying a plant development process comprising a catalyst that comprises one or more of the above bacteria.

Abstract: The presently-disclosed subject matter is directed to biosensors comprising spore-forming bacterial cells and/or spores generated therefrom, a recognition unit within each spore-forming cell for binding an analyte of interest, and a reporter molecule within each spore-forming cell for detecting binding of the analyte of interest, wherein the reporter molecule generates a detectable signal upon binding of the analyte by the recognition element. The presently-disclosed subject matter further provides methods of using the biosensors and systems and kits including the biosensors.

Abstract: The present disclosure defines a method for identifying and/or treating risk and/or occurrence of cardiac defect. As is shown herein, microbiomes are reproducibly and detectably associated with cardiac defect risk factors and changes to the microbiome can directly alter cardiac defect risk. The present disclosure demonstrates that microbial signatures can be used to characterize components of microbiomes that associate with altered risk or occurrence of cardiac defects and to identify treatments to reduce risk or severity of cardiac defects.

Abstract: Hyperblebbing Shigella strains are generated by disrupting one or more components of the Tol-Pal system. The blebs from these strains are useful immunogens for vaccination. The individual proteins found in these blebs can also be used as immunogens.

Abstract: The present invention describes a bacterium belonging to the family Enterobacteriaceae which has L-cysteine-producing ability and has been modified to decrease the activity of a protein encoded by the d0191 gene. This bacterium is cultured in a medium, and L-cysteine, L-cystine, derivatives thereof, or a mixture thereof is collected from the medium.

Abstract: This invention relates to bacteria having a function of reducing the content of heavy metals in plants, a method for reducing the content of heavy metals in plants with the use of such bacteria, and a composition comprising, as an active ingredient, such bacteria.

Abstract: The present invention relates to bacteria cultures and composition comprising one or more cultures of the invention. The invention also relates to methods of washing or cleaning laundry or fabrics and surfaces as well as degrading waste material using a bacteria culture of the invention.

Abstract: The present invention relates to novel bacteria and the uses thereof. The invention particularly relates to Deinococcus bacteria and their use in the pharmaceutical or agro-chemical industries, e.g., for degrading biomass and/or producing metabolites or drugs of industrial interest.

Abstract: This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut micriobiota.

Abstract: Microbial production of pyruvate and metabolites derived from pyruvate in cells exhibiting reduced pyruvate dehydrogenase activity compared to wild-type cells. Acetate and glucose are supplied as a carbon sources.

Abstract: The present invention provides dyes, reactive dyes and labeled reagents that may be used in the detection or quantification of desirable target molecules, such as proteins and nucleic acids. Dyes are provided that may be used free in solution where the binding of the dye to the target molecule provides signal generation. Dyes are also provided that comprise reactive groups that may be used to attach the dyes to probes that will bind to desirable target molecules. The novel dyes of the present invention have been modified by the addition of charged and polar groups to provide beneficial properties.

Abstract: The disclosure relates to strains, compositions and methods for detoxifying a mycotoxin. In another embodiment, the disclosure relates to strains, compositions and methods for alleviating the gastrointestinal inflammatory response resulting from ingestion of mycotoxins. In one embodiment, the strains are Bacillus strains. In another embodiment, the strains are lactic acid bacteria.

Abstract: The invention relates to an infant formula comprising a source of protein in an amount of not more than 2.0 g/100 kcal, a source of lipids, a source of carbohydrate and a probiotic wherein the probiotic is present in an amount equivalent to between 102 and 105 cfu/g of dry formula. The invention further extends to the use of such an infant formula to modulate the immune system of a neonatal infant to promote the development in the first few weeks of the life of the infant of a beneficial intestinal microbiota comparable with that found in breast fed babies as well as to promote the maturation of the immune system of a neonatal infant in the first few weeks of life.

Abstract: Ligand functionalized substrates, methods of making ligand functionalized substrates, and methods of using functionalized substrates are disclosed.

Abstract: The present invention concerns compositions comprising and methods of identification and use of targeting peptides for placenta or adipose tissue. In certain embodiments, the targeting peptides comprise part or all of SEQ ID NO:5-11, SEQ ID NO:13-22 or SEQ ID NO:144. The peptides may be attached to various therapeutic agents for targeted delivery. Adipose-targeting peptides may be used in methods for weight control, inducing weight loss and treating lipodystrophy syndrome. Adipose-targeting may also be accomplished using other binding moieties selectively targeted to adipose receptors, such as a prohibitin receptor protein complex. Placenta-targeting peptides may be used to interfere with pregnancy, induce labor and/or for targeted delivery of therapeutic agents to placenta and/or fetus. In other embodiments, receptors identified by binding to placenta-targeting peptides may be used to screen compounds for potential teratogenicity.

Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the present invention relates to methods for vitrifying biological preparations, including peptides, antigens, antibodies, cells, and the like.

Abstract: The present invention is related to an isolated chemolithotrophic bacterium belonging to species Acidithiobacillus thiooxidans named Licanantay, deposited in Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH-DSMZ with number DSM 17318, and its use in pure form or in mixtures that contains it for bioleaching processes of minerals or sulfured metallic species concentrates. This Licanantay strain DSM 17318 has sulfur-oxidizing activity in both primary and secondary sulfured minerals, especially in the case of chalcopyrite, covellite, bornite, chalcocite, enargite and tennantite.

Abstract: A class of integral membrane proteins, referred to as Mistic polypeptides, their variants, fusion proteins including a Mistic polypeptide domain, and nucleic acid molecules encoding Mistic polypeptides and Mistic fusion proteins are disclosed herein. Also described are methods of using Mistic polypeptides and Mistic fusion proteins to produce and/or isolate recombinant proteins (including without limitation classes of eukaryotic proteins that have previously been intractable to recombinant bacterial expression, such as, eukaryotic integral membrane proteins).

Abstract: Biofungicide composition derived from a biologically pure culture of a Chilean bacterial isolate obtained from the skin of grapes, corresponding to Serratia plymuthica CCGG2742, to be used as an environmentally friendly biological control agent against fungal diseases of vegetables, in particular fruits susceptible to the infection of Botrytis cinerea, efficiently preventing the germination of conidia and the proliferation of mycelia of said phytopathogenic fungus, furthermore protecting the plant's leaves and fruits from the infection by the same fungus, and having the potential of being used in the biological control of other phytopathogenic fungus and microorganisms.

Abstract: The disclosed technology relates to a genetically engineered biological indicator, comprising: at least one test organism and at least one reporter gene suitable for producing an indicator enzyme, the reporter gene being taken up by the test organism; and at least one repressor gene that inhibits expression of the reporter gene until the reporter gene is exposed to at least one inducer. A process and an apparatus for using the biological indicator are disclosed.

Abstract: Disclosed are a method for producing polyhydroxyalkanoates (PHAs) using a halobacterium belonging to the genus Halomonas, wherein the halobacterium can grow in a medium consisting of an inorganic salt and a single organic carbon source and having a pH of 8.8 to 11, and produce PHAs in an amount of 20 wt. % or more based on the dry cell weight, and the halobacterium is cultured in an alkaline medium containing an inorganic salt and one or more organic carbon sources to produce PHAs in an amount of 20 wt. % or more based on the dry cell weight; and the halobacterium belonging to the genus Halomonas, which can grow in a medium consisting an inorganic salt and a single organic carbon source and having a pH of 8.8 to 11, and produce PHAs in an amount of 20 wt. % or more based on the dry cell weight.

Abstract: The present invention provides a microorganism belonging to the genus Enterobacter, wherein the microorganism has an ability to assimilate glycerol to produce hydrogen gas and 1,3-propanediol, and wherein the microorganism is capable of assimilating glycerol in the presence of 10 mass % glycerol.

Abstract: Provided herein are methods for inducing and stabilizing an enzyme activity. Optionally, the enzyme is in a microorganism capable of producing the enzyme. In some embodiments, the enzyme can be nitrile hydratase, amidase, or asparaginase I. Provided are compositions comprising enzymes or microorganisms having induced and/or stabilized activity. Also provided are methods of delaying a plant development process by exposing a plant or plant part to the enzymes or microorganisms having induced and/or stabilized activity.

Abstract: The invention provides biosynthetic routes to xylitol production that do not require pure D-xylose for synthesis and that can utilize inexpensive substrates such as hemicellulose hydrolysates.

Abstract: The present invention relates to a novel selective synthesis of 9?-hydroxy-steroid derivatives of the general formula (I) (I)—wherein the meaning of -A-A?- is —CH2—CH2— or —CH?CH— group—by the bioconversion of compounds of the general formula (II) (II) wherein the meaning of -A-A?- is —CH2—CH2— or —CH?CH— group—by using Nocardia farcinica bacterium strain, deposition number of which is NCAIM (P)—B 001342, as hydroxylating microorganism in the bioconversion.

Abstract: A method for transforming algal or cyanobacterial cells, comprising mixing a polynucleotide for transforming the cells with the polynucleotide; performing microporation by applying a plurality of electrical pulses to the cells with a microporation apparatus; and incubating said polynucleotide with the cells after said applying said electrical pulses.

Abstract: A cell culture article comprises a substrate having a micro-structured surface and a thin hydrophobic elastomeric coating disposed on the substrate. The coating forms a micro-structured cell culture surface and is sufficiently thin to reduce absorption of hydrophobic molecules from an aqueous medium in contact with the coating, relative to articles fabricated entirely from the hydrophobic elastomer.

Abstract: Compositions comprising microbiological strains and cultures and methods of use thereof are provided herein. Certain strains, cultures, and compositions thereof are useful for the control of head blight disease, for example, of various crop plants. Biological control compositions, and methods of use thereof to prevent, inhibit or treat the development of plant pathogens or disease and for preserving plant yield, are also provided.

Abstract: A method for microbiologically producing zeaxanthin at high concentration and low cost while suppressing production of gluconic acid is presented. Specifically, a method for producing carotenoids containing zeaxanthin by culturing a bacterium producing carotenoids containing zeaxanthin in a medium containing biotin is provided.

Abstract: The invention features methods for producing isoprene from cultured cells using a feedback-resistant mevalonate kinase polypeptide, such as an archaeal mevalonate kinase polypeptide. The resulting isoprene compositions may have increased yields and/or purity of isoprene.

Abstract: A method for retention testing sterilizing grade filters comprises: a) providing a stock of Acholeplasma laidlawii; b) growing up the stock of A. laidlawii for about 24 hours or less in a single serum-free growth medium that supports cell growth to a high titer and yields a cellular morphology where the cells are small, deaggregated and spherical, thereby producing a bacterial culture; c) challenging a test filter by filtering the bacterial culture through the test filter at a known challenge level, thereby producing a filtrate downstream of the test filter; and d) detecting concentration of A. laidlawii in the filtrate. Serum-free growth media for cultivating or storing A. laidlawii are also described.

Abstract: The invention relates to genetically engineered cells, and to proteins and genes useful in the production of tetracycline compounds, to methods of producing tetracycline compounds, and to tetracyclines thereby produced. The present invention is based on the cloning and heterologous expression of genes encoding the chelocardin biosynthetic pathway.

Abstract: The present invention relates to an attenuated strain of Ehrlichia canis and a vaccine comprising said attenuated strain for protection of mammals against ehrlichiosis. The invention further relates to methods of preventing ehrlichiosis and of attenuating the pathogenicity Ehrlichia canis.

Abstract: The present invention provides a scalable process for producing a concentrate containing a mass of a farnesylated dibenzodiazepinone by fermenting in an aqueous culture medium a strain of a microorganism that is capable of producing the farnesylated dibenzodiazepinone, upon completion of fermentation harvesting the fermentation broth and extracting the fermentation broth to provide an extract, and thereafter treating the extract to form the concentrate. The concentrate so produced may be utilized in downstream processes for producing pharmaceutical compounds. A strain of a Micromonospora species capable of producing a farnesylated dibenzodiazepinone at a high yield rate is provided, together with culture media for culturing microorganisms, and fermentation conditions for production of the farnesylated dibenzodiazepinone of the concentrate.

Abstract: Provided herein are methods and systems for interfering with viability of bacteria and related compounds and compositions.

Abstract: The present invention provides live, attenuated Mycoplasma gallisepticum bacteria that exhibit reduced expression of a protein identified as MGA_0621. In certain embodiments, the attenuated bacteria may additionally exhibit reduced expression of one or more proteins selected from the group consisting of pyruvate dehydrogenase, phosphopyruvate hydratase, 2-deoxyribose-5-phosphate aldolase, and ribosomal protein L35, relative to a wild-type M. gallisepticum bacterium. Also provided are vaccines and vaccination methods involving the use of the live, attenuated M. gallisepticum bacteria, and methods for making live attenuated M. gallisepticum bacteria. An exemplary live, attenuated strain of M. gallisepticum is provided, designated MGx+47, which was shown by proteomics analysis to exhibit significantly reduced expression of MGA_0621, and was shown to be safe and effective when administered as a vaccine against M. gallisepticum infection in chickens.

Abstract: The present invention relates to novel polyamino polyketide antibiotics, methods of their production as well as methods of using these antibiotics, for example, for inhibition or removal of biofilm formation or for treating bacterial infection with these antibiotics.

Abstract: The invention related to compositions and methods for the in vivo production of polypeptides comprising one or more unnatural amino acids. Specifically, the invention provides plasmid systems for the efficient eubacterial expression of polypeptides comprising one or more unnatural acids at genetically-programmed positions.

Abstract: Granulysin peptides are small antimicrobial agents with potent activity. A pharmaceutical composition comprising granulysin peptides as an active agent is administered therapeutically to a patient for exfoliation, e.g. for the treatment of skin lesions.

Abstract: There are disclosed a culture media and culture supplements for cultivating microorganisms, including Listeria spp and methods for culturing microorganisms including Listeria spp. There are also disclosed methods for detecting the presence of microorganisms including Listeria spp in samples.

Abstract: The present invention relates to isolated organ-specific feline endothelial cells. Specifically, the present invention relates to established organ-specific feline endothelial cells. The present invention also relates to organ-specific feline endothelial cells derived from micro- and macro-vascularisation. The present invention also relates to methods for screening molecules, for studying pathologies and for producing pathogens using same.

Abstract: The invention provides a method of inhibiting a bacterial RNA polymerases. The invention has applications in control of bacterial RNA polymerase activity, control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, and antibacterial therapy.